Association between extent of thiazolidinedione exposure and risk of acute myocardial infarction

Pharmacotherapy

Volumn 29, Issue 7, 2009, Pages 775-783

  Dore, David D ^a,b   Trivedi, Amal N ^b   Mor, Vincent ^b   Lapane, Kate L ^b,c  

^a i3 Drug Safety   (United States)

^b BROWN UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Medicaid analytic extract; Myocardial infarction; Pharmacoepidemiology; Pioglitazone; Rosiglitazone; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTITHROMBOCYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL; CORTICOSTEROID; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HYPNOTIC AGENT; HYPOCHOLESTEROLEMIC AGENT; INSULIN; METFORMIN; NITRIC ACID DERIVATIVE; OPIATE; PIOGLITAZONE; ROSIGLITAZONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SULFONYLUREA;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EXPOSURE; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; SAMPLING; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK; THIAZOLIDINEDIONES; TIME FACTORS; UNITED STATES;

EID: 67650796163     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.7.775     Document Type: Article

References (37)

1. U.S. Food and Drug Administration. FDA news. FDA adds boxed warning for heart-related risks to anti-diabetes drug Avandia. Available from www.fda.gov/bbs/topics/NEWS/2007/ NEW01743.html. Accessed November 14, 2007.
2. McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 2007;16(7):711-725 (Pubitemid 47180361)
3. Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Pharmacoepidemiol Drug Saf 2007;16(5): 504-512 (Pubitemid 46824271)
4. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356(24):2457-2471 (Pubitemid 46919772)
5. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298(10):1180-1188 (Pubitemid 47403104)
6. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet 2005;366(9493):1279-1289 (Pubitemid 41416583)
7. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis. N Engl J Med 2007;357(1):28-38. (Pubitemid 47026732)
8. GlaxoSmithKline. Avandia (rosiglitazone maleate) tablets prescribing information. Research Triangle Park, NC; 2007. Available from www.fda.gov/cder/foi/label/2007/021071s023lbl.pdf. Accessed May 18, 2007.
9. Takeda Pharmaceuticals North America, Inc. Actos (pioglitazone hydrochloride) tablets prescribing information. Deerfield, IL; revised September 2007. Available from www.actos.com/actos/prescribinginfo.aspx. Accessed November 15, 2007.
10. Nichols G, Gomez-Caminero A. Weight changes following the initiation of new anti-hyperglycaemic therapies. Diabetes Obes Metab 2007;9(1):96-102. (Pubitemid 44921047)
11. Patel J, Anderson R, Rappaport E. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1999;1(3):165-72
12. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 2004;148(1):99-104. (Pubitemid 38900487)
13. Richardson DB. An incidence density sampling program for nested case-control analyses. Occup Environ Med 2004; 61(12):e59-64.
14. Robins JM, Gail MH, Lubin JH. More on "biased selection of controls for case-control analyses of cohort studies." Biometrics 1986;42(2):293-299
15. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364(9438):937-952 (Pubitemid 39208455)
16. Rosengren A, Hawken S, Ounpuu S, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 2004;364(9438):953-962 (Pubitemid 39208456)
17. Suissa S, Assimes T, Brassard P, Ernst P. Inhaled corticosteroid use in asthma and the prevention of myocardial infarction. Am J Med 2003;115(5):377-381 (Pubitemid 37311255)
18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5):373-383 (Pubitemid 17055592)
19. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993;46(10):1075-9, discussion 1081-1090 (Pubitemid 23302074)
20. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131):837-53. (Erratum in Lancet 1999;354(9178):602.)
21. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration cooperative study. N Engl J Med 1983;309(7):396-403.
22. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342(3):145-53. (Errata in N Engl J Med 2000;342(18):1376 and 2000;342(10):748.)
23. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction: development of myocardial infarction. Am J Cardiol 1985;56(14):23G-6.
24. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349(6):523-534 (Pubitemid 36951364)
25. Meier CR, Derby LE, Jick SS, Vasilakis C, Jick H. Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA 1999;281(5):427-431 (Pubitemid 29069440)
26. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air force/Texas coronary atherosclerosis prevention study. JAMA 1998;279(20):1615-1622 (Pubitemid 28248586)
27. American Diabetes Association. Standards of medical care in diabetes: 2009. Diabetes Care 2009;32(suppl 1):S13-61.
28. Rothman KJ, Greenland S. Modern epidemiology, 2nd ed. Philadelphia: Lippincott-Raven, 1998.
29. Yola M, Lucien A. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994;47(7):731-737 (Pubitemid 24236255)
30. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002;106(3):388-91
31. Mosca L, Linfante AH, Benjamin EJ, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 2005;111(4):499-510. (Pubitemid 40204436)
32. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355(23):2427-2443 (Pubitemid 44903747)
33. Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Safety 2007;16(10):1065-1071 (Pubitemid 350020057)
34. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158(9):915-920 (Pubitemid 37323253)
35. Crystal S, Akincigil A, Bilder S, Walkup JT. Studying prescription drug use and outcomes with Medicaid claims data: strengths, limitations, and strategies. Med Care 2007;45(10 suppl 2):S58-65.
36. McKenzie DA, Semradek J, McFarland BH, Mullooly JP, McCamant LE. The validity of Medicaid pharmacy claims for estimating drug use among elderly nursing home residents: the Oregon experience. J Clin Epidemiol 2000;53(12):1248-1257 (Pubitemid 32007841)
37. Ray WA, Griffin MR. Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol 1989;129(4):837-49